Page 104 - Quest Diagnostics News Today

Laboratory Corp of America Holdings cut its annual profit forecast on Thursday following the spin off of its clinical development business, Fortrea. The lab operator has been struggling...

Bahl & Gaynor Inc. boosted its stake in Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 6.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 175,046 shares of the medical research company’s stock after acquiring an additional 11,312 shares during […]

Bahl & Gaynor Inc. boosted its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX – Free Report) by 6.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 175,046 shares of the medical research company’s stock after acquiring an additional 11,312 shares […]

Operator: Welcome to the Quest Diagnostics Second Quarter 2023 Conference Call. At the request of the company, this call is being recorded. [Operator Instructions].

While reporting financial results for the second quarter on Wednesday, Quest Diagnostics Inc. (DGX) raised its adjusted earnings and revenue guidance for the full-year 2023.

Real-time index price for S&P 500 Utilities [Sector] (SRUT), along with buy or sell indicators, analysis, charts, historical performance, news and more

By Sabela Ojea Quest Diagnostics on Wednesday posted a decline in revenue in a second quarter marked by lower productivity and higher costs due to high...

/PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the worlds leading provider of diagnostic information services, announced today financial results...

Quest Diagnostics Incorporated (NYSE:DGX – Free Report) – Equities researchers at Zacks Research decreased their FY2023 earnings estimates for shares of Quest Diagnostics in a research report issued to clients and investors on Monday, July 24th. Zacks Research analyst M. Mondal now forecasts that the medical research company will post earnings per share of $8.55 […]

Using novel technology, a new test aims to sharpen predictions about the aggressiveness of individual prostate cancers.